Showing 3371-3380 of 5910 results for "".
- Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trialshttps://modernod.com/news/dopavision-closes-e12-million-series-a-round-to-advance-digital-childhood-myopia-therapeutic-through-clinical-trials/2479372/Dopavision announced the closing of a €12 million Series A financing round. The proceeds will be used to fund the clinical development of MyopiaX, the company’s lead product in childhood myopia, with the goal to demonstrate its safety and efficacy in clinical studies and advance this innova
- Aurion Biotech Appoints Professor Shigeru Kinoshita, MD, PhD, to Its Medical Advisory Boardhttps://modernod.com/news/aurion-biotech-appoints-professor-shigeru-kinoshita-md-phd-to-its-medical-advisory-board/2479369/Shigeru Kinoshita, MD, PhD, has joined the medical advisory board at Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases. Professor Kinoshita is the inventor of Aurion Biotech’s lead candidate, cell therapy for
- First-Of-Its-Kind Visual Prosthesis Brain Implant Developed in Chicago Moves to Clinical Trialhttps://modernod.com/news/first-of-its-kind-visual-prosthesis-brain-implant-developed-in-chicago-moves-to-clinical-trial/2479367/The Intracortical Visual Prosthesis (ICVP) is an implant that connects directly to the brain’s visual cortex, bypassing the retina and optic nerves. The National Institutes of Health has awarded Illinois Tech researchers $2.5 million for the first year of a 3-year project that includes implanting
- AMA Assigns CPT Code to Software Designed to Treat Adult Amblyopia (Lazy Eye)https://modernod.com/news/ama-assigns-cpt-code-to-software-designed-to-treat-adult-amblyopia-lazy-eye/2479361/RevitalVision announced that its standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical
- Sight Sciences Pitches $150M IPO for Its Glaucoma, Dry Eye Deviceshttps://modernod.com/news/sight-sciences-pitches-150m-ipo-for-its-glaucoma-dry-eye-devices/2479355/Sight Sciences hopes to see its way to nearly a $1 billion valuation through a $150 million Nasdaq IPO, according to a Fierce Biotech report. By going public, the Menlo Par
- Pfizer Plans to Seek FDA Nod for COVID-19 Booster Next Month as Delta Spreadshttps://modernod.com/news/pfizer-plans-to-seek-fda-nod-for-covid-19-booster-next-month-as-delta-spreads/2479354/Pfizer’s chief scientific officer Mikael Dolsten indicated Thursday that the company plans to seek an FDA emergency-use authorization next month for a third dose of its COVID-19 vaccine BNT162b2, according to a FirstWord report. The mRNA-based vaccine, partnered with BioNTech, is cur
- Ocugen Climbs on Phase 3 COVID Vaccine Data, Hitting Back at Delta Varianthttps://modernod.com/news/ocugen-climbs-on-phase-3-covid-vaccine-data-hitting-back-at-delta-variant/2479348/After seeing its stock fall consistently over the past few months, Ocugen and partner Bharat Biotech have posted some encouraging data from their pandemic vaccine Covaxin, according to a FierceBiotech report. The latest look from its lat
- EyePoint Pharmaceuticals Reports Positive 30-Day Safety Results for All Cohorts From DAVIO Trial of EYP-1901 for Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results-for-all-cohorts-from-the-davio-trial-of-eyp-1901-for-wet-amd/2479344/EyePoint Pharmaceuticals announced positive safety results from its phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (AMD). All dose cohorts have reached at least 30-day post-dosing foll
- Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trialhttps://modernod.com/news/nicoxs-ncx-470-demonstrates-significant-intraocular-pressure-lowering-in-dolomites-phase-2-glaucoma-trial/2479333/Nicox presented results from the Dolomites phase 2 clinical trial showing that NCX 470, a novel nitric oxide (NO)-donating prostaglandin analog (PGA), produced significantly greater IOP lowering effects in glaucoma patients compared with the current standard of care, latanoprost. In Dolom
- Recycling of the Eye’s Light Sensors Is Faulty in Progressive Blindness of Older Adults, University of Maryland School of Medicine Researchers Showhttps://modernod.com/news/recycling-of-the-eyes-light-sensors-is-faulty-in-progressive-blindness-of-older-adults-university-of-maryland-school-of-medicine-researchers-show/2479329/With the National Eye Institute reporting that about 11 million older adults in the U.S. endure a condition that leads to progressive blindness, known as age-related macular degeneration, University of Maryland School of Medicine (UMSOM) researchers are starting to understand what goes wrong in t